Colorectal Cancer Clinical Trials

A listing of Colorectal Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 444 clinical trials
A Study of NX-1607 in Adults With Advanced Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

systemic therapy
measurable disease
carcinoma
growth factors
fallopian tube
  • 0 views
  • 07 Jun, 2022
  • 6 locations
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors

The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.

lung carcinoma
nivolumab
cancer
carcinoma
progressive disease
  • 0 views
  • 20 Jun, 2022
  • 9 locations
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer (GEN602)

This Phase I/Ib study is a Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients with Advanced Solid Tumors or Lymphoma

mammogram
antineoplastic agents
gz17-6.02
cancer chemotherapy
kidney function test
  • 40 views
  • 23 May, 2022
  • 1 location
Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING) (GOING)

, and thereby blocks tumour cell proliferation. Regorafenib has shown in clinical trials an acceptable benefit-risk across different tumor types, including colorectal cancer (CRC

RET
nivolumab
cancer
regorafenib
TACE
  • 0 views
  • 24 May, 2022
  • 5 locations
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors

This is a dose escalation, MTD expansion (Phase 1b) and cohort expansions (Phase 2) study to assess the safety and tolerability of a combination of NAP with durvalumab in subjects with selected advanced or metastatic solid tumors.

white blood cell count
systemic therapy
head and neck carcinoma
neuropathy
mammogram
  • 15 views
  • 16 Jun, 2022
  • 3 locations
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

The primary purpose of this study is to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies that have progressed despite standard therapy or for which no effective standard therapy exists

systemic therapy
melanoma skin
immunologic adjuvant
immunomodulator
cancer
  • 1231 views
  • 20 Jun, 2022
  • 10 locations
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (KEYNOTE A60)

The main purposes of Phase 1b of this study are to determine the following in participants with advanced solid tumors: Safety and tolerability of NT-I7 in combination with pembrolizumab Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) The main purpose of Phase 2a of this study is …

gemcitabine
cancer chemotherapy
monoclonal antibodies
ovarian cancer
tyrosine
  • 24 views
  • 15 Jun, 2022
  • 7 locations
A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors

This is an open label, multi-cohort, multicenter Phase II study, the purpose of this study is to assess the efficacy and safety of envofolimab in combination with BD0801 injection with/without chemotherapy for the treatment of advanced solid tumors

  • 0 views
  • 27 Apr, 2022
  • 19 locations
MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma (COTESARC)

The proposed study is a two-step trial with 1) a safety run in part conducted in pediatric patients and 2) a Phase II part in adult and pediatric patients aiming to evaluate the safety and clinical activity of atezolizumab + cobimetinib in advanced/metastatic soft tissue sarcomas.

epithelioid sarcoma
neutrophil count
cancer chemotherapy
cancer
mpnst
  • 5 views
  • 23 Apr, 2022
  • 4 locations
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

TTX-080-01 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor) or cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies. …

cetuximab
cancer
primary cancer
solid tumour
measurable disease
  • 0 views
  • 09 Jun, 2022
  • 22 locations